Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

24 Mar 2010 11:15

RNS Number : 0981J
Credit Suisse Securities (Eur) Ltd
24 March 2010
 

FORM 38.5 (a)

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITH RECOGNISED INTERMEDIARY STATUS

DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(a) of the Takeover Code)

1. KEY INFORMATION

Name of exempt principal trader

Credit Suisse Securities (Europe) Limited

Company dealt in

Ark Therapeutics Group PLC

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary Shares

Date of dealing

23-Mar-2010

2. DEALINGS (Note 2)

(a) Purchases and sales

Total number of securities purchased

Highest price paid (Note 3)

Lowest price paid (Note 3)

12,000

0.1175 (GBP)

0.1175 (GBP)

 

Total number of securities sold

Highest price received (Note 3)

Lowest price received (Note 3)

6,000

0.1175 (GBP)

0.1175 (GBP)

(b) Derivatives transactions (other than options)

Product name, e.g. CFD

Long/short (Note 4)

Number of securities (Note 5)

Price per unit (Note 3)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 3)

3. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Date of disclosure

24-Mar-2010 09:23:46

Contact name

Eliades,Vassilis D/Carolyn Collins

Telephone number

+44 7888 6659

Name of offeree/offeror with which connected

Ark Therapeutics Group PLC

Nature of connection (Note 6)

ADVISOR

Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMSELFFLFSSEFD
Date   Source Headline
6th Jun 20122:41 pmRNSBlocklisting Interim Review
18th May 201212:02 pmRNSHolding(s) in Company
18th May 201212:01 pmRNSDirector Dealings
18th May 201211:57 amRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
16th May 20127:00 amRNSCompletion of Phase 1 Study
2nd May 20127:00 amRNSGrant and Patent Update
25th Apr 20127:00 amRNSRegulatory Approval of Manufacturing Suite
17th Apr 20122:36 pmRNSDirector/PDMR Shareholding
10th Apr 20127:00 amRNSNew Board Appointment
2nd Apr 20123:25 pmRNSAnnual Information Update
26th Mar 20127:00 amRNSChange of Broker Name
15th Mar 20124:09 pmRNSDirector/PDMR Shareholding
13th Mar 20124:16 pmRNSBoard Changes
12th Mar 20127:00 amRNSFinal Results
23rd Feb 20124:29 pmRNSHolding(s) in Company
9th Feb 201211:10 amRNSNotice of Results
8th Feb 20127:00 amRNSUS patent for Neuropilin-1 receptor
4th Jan 20127:00 amRNSManufacturing Update
7th Dec 201111:48 amRNSDirector/PDMR Shareholding
5th Dec 20112:35 pmRNSBlocklisting Interim Review
9th Nov 20117:00 amRNSInterim Management Statement
3rd Nov 20117:00 amRNSManufacturing agreement
16th Sep 20114:41 pmRNSSecond Price Monitoring Extn
16th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20117:00 amRNSRe Agreement
24th Aug 20115:29 pmRNSHalf Yearly Report on National Storage Mechanism
24th Aug 20117:00 amRNSHalf Yearly Report - Part 2
24th Aug 20117:00 amRNSHalf Yearly Report - Part 1
1st Aug 20114:31 pmRNSHolding(s) in Company
29th Jul 20114:40 pmRNSSecond Price Monitoring Extn
29th Jul 20114:35 pmRNSPrice Monitoring Extension
25th Jul 20114:40 pmRNSSecond Price Monitoring Extn
25th Jul 20114:35 pmRNSPrice Monitoring Extension
18th Jul 20113:10 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSWins ?5.3 million EU Framework Programme 7 Grant
6th Jul 20117:00 amRNSArk receives Finnish Grants
4th Jul 20117:00 amRNSGrant of US patents and milestone payments
13th Jun 20114:40 pmRNSSecond Price Monitoring Extn
13th Jun 20114:35 pmRNSPrice Monitoring Extension
3rd Jun 201111:57 amRNSBlocklisting Interim Review
17th May 20117:00 amRNSInterim Management Statement
9th May 20113:28 pmRNSAGM Results
31st Mar 20111:43 pmRNSAnnual Information Update
30th Mar 20111:08 pmRNSDirector/PDMR Shareholding
24th Mar 20113:40 pmRNSAnnual Financial Report
9th Mar 20117:00 amRNSFinal Results
3rd Mar 20117:00 amRNSAppointment of CFO
2nd Mar 20117:00 amRNSDisposal
28th Feb 201111:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.